Purpose: To develop echo-planar spectroscopic imaging (EPSI) with large spectral width and accomplish highresolution imaging of 2-hydroxyglutarate (2HG) at 7 T. Methods: We designed a new EPSI readout scheme at 7 T. Data were recorded with dual-readout alternated gradients and combined according to the gradient polarity. Following validation of its performance in phantoms, the new readout scheme, together with previously reported 2HG-optimized magnetic resonance spectroscopy (point-resolved spectroscopy echo time of 78 ms), was used for time-efficient and high-resolution imaging of 2HG and other metabolites in five glioma patients before treatment. Unsuppressed water, acquired with EPSI, was used as reference for multichannel combination, eddy-current compensation, and metabolite quantification. Spectral fitting was conducted with the LCModel using in-house calculated basis sets. Results: Using a readout gradient strength of 9.5 mT/m and slew rate of 90 mT/m/ms, dual-readout alternated gradients EPSI permitted 1638-Hz spectral width with 6 Â 6 mm 2 inplane resolution at 7 T. Phantom data indicated that dualreadout alternated gradients EPSI provides proper metabolite signals and induces much less frequency drifts than conventional EPSI. For a spatial resolution of 0.5 mL, 2HG was detected in tumors with precision (Cramer-Rao lower bound < 10%). The 2HG was estimated to be 2.3 to 3.3 mM in tumors of three patients with biopsy-proven isocitrate dehydrogenase (IDH) mutant gliomas. The 2HG was undetectable in an IDH wild-type glioblastoma. For a radiographically suggested glioma, the estimated 2HG of 2.3 6 0.2 mM (CramerRao lower bound < 10%) indicated that the lesion may be an IDH mutant glioma. Conclusions: The data indicated that the dual-readout alternated gradients EPSI can provide reliable high-resolution imaging of 2HG in glioma patients at 7 T in vivo.
INTRODUCTION
Most World Health Organization grade II and III gliomas and secondary glioblastomas harbor isocitrate dehydrogenase (IDH) mutations in cytosol (IDH1) and mitochondria (IDH2), and the mutations are associated with longer survival and better response to therapy compared with IDH wild-type tumors (1) (2) (3) . The IDH mutation gives rise to NADPH-dependent reduction of a-ketoglutarate to 2-hydroxyglutatrate (2HG), leading to elevation of 2HG by orders of magnitude (4) (5) (6) . Thus, 2HG provides a novel imaging biomarker for identifying IDH mutant gliomas noninvasively. In vivo detection of 2HG was reported in many recent studies, which included single-voxel 1 H magnetic resonance spectroscopy (MRS) 3T and 7T (7) (8) (9) (10) (11) (12) (13) (14) and multivoxel MRS imaging (MRSI) at 3 T (7, 11, 15) . The spatial resolution in these 2HG imaging studies was relatively low (voxel size ! 1.5 mL). Gliomas are highly heterogeneous and infiltrative in malignant transformation. The capability to rapidly image 2HG with high resolution has great potential for patient care and cancer research. 1 H echo planar spectroscopic imaging (EPSI) (16) has been used widely for fast and high-resolution mapping of brain metabolites at 3 T and 4 T (17, 18) . Imaging of J-coupled spin metabolites at these intermediate filed strengths remains challenging, largely because of the low signal strengths and spectral overlaps (19) . Recent studies showed that EPSI at 7 T confers significantly improved signal gain and spectral resolution (20, 21) , but the in vivo applicability in human MR scanners is quite limited as a result of small spectral widths, which are insufficient for covering the spectral regions of interest (22) .
Several EPSI approaches were proposed for data acquisition and reconstruction. First, odd/even echo editing was conventionally used for neuro-metabolic imaging at 1.5 T, 3 T, and 4 T (17) (18) (19) 22) . The echo editing results in a halved spectral width with respect to the acquisition dwell time. Second, the interlaced Fourier transformation approach maintained the full spectral width (23, 24) , but this was achieved by ignoring the prevailing gradient delay artifacts. Third, a dual-readout EPSI with flyback gradients (25) was proposed to increase the spectral width. Data acquired using two sets of interleaved readout gradients with flyback gradients were combined to a single set of data, leading to a spectral width greater by two-fold with respect to the acquisition dwell time. This approach was used recently for brain-tumor metabolic imaging at 7 T, with in-plane resolution of 10 Â 10 mm 2 (21) . Finally, time-shift EPSI was proposed for increasing spectral width (26, 27) .
In this paper, we propose a new EPSI approach that was designed from the conventional bipolar readout gradient and dual-readout approaches. Taking advantage of the two published schemes, this new method provides increased spectral width, high signal-to-noise ratio (SNR), and small burden on the gradient system, compared with the published EPSI methods. The new EPSI scheme, combined with our previously reported 2HG-optimized MRS sequence (13) , is demonstrated for highresolution imaging of 2HG and other metabolites at 7 T.
Following phantom validation of the performance, preliminary data from five brain tumor patients are presented.
THEORY

Conventional EPSI
In conventional EPSI, data acquisition may undergo using an alternated-gradient readout with a dwell time of Dt, as shown in Figure 1a . The data acquired during the positive-and negative-polarity gradients are separated into odd and even-echo sets, and each data set is processed for eddy-current compensation and phase correction. The two sets of data may then be averaged to improve SNR. Ghost artifacts caused by asymmetries in gradient switching can be removed with the odd/even echo editing (28) . The dwell time of the reconstructed data is twice (2Dt) the acquisition dwell time, resulting in spectral width of 1/(2Dt). The spectral width of this conventional EPSI in human MR scanners is typically approximately 1 kHz (18, 22) , which is approximately 3.3 ppm at 7 T.
Dual-Readout Alternated Gradients (DRAG) EPSI
Figure 1b depicts a new EPSI readout scheme. The scheme consists of two sets of readouts: one using the conventional alternated gradient and the other using a FIG. 1. a: Conventional EPSI readout scheme is depicted with the data-processing procedures. Following a VOI prescription sequence (e.g., PRESS), odd-number echoes (e.g., O 1 , O 2 , O 3 ,) and even-number echoes (e.g., E 1 , E 2 , E 3 ) are acquired with a dwell time of Dt, and combined with odd/even echo editing, leading to a set of echo data with a spectral width of 1/(2Dt). b: Newly designed EPSI readout scheme is shown together with echo editing procedures. Two sets of data are recorded using DRAG with opposite polarity, and the positive-gradient data (e.g., P 1 , P 2 , P 3 ) and negative-gradient data (e.g., N 1 , N 2 , N 3 ) are combined into a set of data, leading to spectral width of 1/Dt. polarity-reversed gradient. The data are then sorted into two data sets according to the gradient polarity (i.e., positive-gradient data and negative-gradient data). Following eddy-current compensation and phase correction, the two sets of data are averaged, leading to a set of EPSI data with spectral width of 1/Dt, greater by two-fold compared with conventional EPSI.
METHODS
The MR experiments were carried out in a human whole-body 7T MR scanner (Philips Medical Systems, Cleveland, OH) using a quadrature transmit (4-kW radiofrequency (RF) amplifier) and 32-channel receive head coil (Nova Medical, Wilmington, MA). The gradient system offered maximum amplitude of 40 mT/m, with maximum slew rate of 200 mT/m/ms. In vitro MRSI experiments were performed in a GE Braino phantom (GE Medical Systems, Milwaukee, WI) (10-cm diameter) and a 6-cm-diameter spherical phantom with 2HG (10 mM) and Gly (20 mM). The phantom scans included conventional phase-encoded MRSI, conventional EPSI, and DRAG EPSI.
Five glioma patients were enrolled, including a 60-year-old male with IDH1-mutated grade-II oligodendroglioma (Patient 1), a 47-year-old female with IDH1-mutated grade-II oligodendroglioma (Patient 2), a 58-year old male with IDH1-mutated grade-II oligoastrocytoma (Patient 3), a 50-year-old male with radiographically suggested glioma (Patient 4), and a 40-year-old male with IDH wild-type glioblastoma (Patient 5). Other than Patient 4, the four patients had biopsy or surgery after the MR scans, from which the tumor type and IDH mutational status were obtained. The MR scans were conducted before chemotherapy and/or radiation treatments. Two-dimensional MRS imaging was obtained with one-dimensional imaging by DRAG-EPSI (Fig. 1b) and another one-dimensional imaging using phase-encoding gradients. The DRAG EPSI was preceded by prescription of a volume of interest (VOI) using our previously reported 7T 2HG-optimized point-resolved spectroscopy (PRESS) sequence (13) , which had the RF pulse envelopes of our 3T 2HG MRS study (10) (Fig. 1d) . The PRESS sequence included an 8.8-ms 90 RF pulse (bandwidth 4.7 kHz) and two 12-ms 180 RF pulses (bandwidth 1.4 kHz) at RF field intensity (B 1 ) of 15 mT. The echo-planar readout gradient consisted of 512 alternating trapezoidal gradients with amplitude of 9.5 mT/m and slope of 90 mT/m/ms (slope length of 105 ms and plateau length of 400 ms). The data of opposed-polarity readouts were acquired in an interleaved fashion. The spectral width of the DRAG EPSI was 1638 Hz (5.5 ppm at 7 T). Flip angle calibration was performed on the PRESSprescribed VOI using a vendor-supplied T 1 insensitive double-stimulated-echo method (29) . Water suppression was obtained with variable power and optimized relaxation delays. Up to second-order B 0 shimming was carried out on the VOI using a vendor-supplied tool. Watersuppressed DRAG-EPSI was acquired with the following parameters: PRESS echo time (TE) ¼ 78 ms (TE 1 ¼ 58 ms The scan time was 16 min, of which 8 min was spent for each of the two readouts. Depending on the tumor size, the VOI ranged from 60 Â 60 to 90 Â 90 mm 2 . Unsuppressed-water imaging data were acquired with VOI prescription by TE ¼ 78 ms PRESS using DRAG EPSI and by TE ¼ 13 ms stimulated echo acquisition mode (STEAM) using conventional EPSI (scan times of 2 and 1 min, respectively). T 2 -weighted fluid attenuated inversion recovery imaging (FLAIR) was acquired for tumor identification (TR/TE/inversion time (TI) ¼ 11,000/ 93/2800 ms; FOV ¼ 230 Â 230 mm 2 ; slice thickness ¼ 5 mm; 20 transverse slices). B 1 map was obtained using a dual flip angle method (30) .
The 2D k-space data were zero-filled to 66 Â 60 matrix and subsequently apodized with a 2D Hamming function. The time domain data were zero-filled to 2048 points and apodized with a 3-Hz exponential function. Eddy-current compensation and multichannel combination were conducted with in-house computer scripts using the unsuppressed PRESS DRAG-EPSI water as reference, after which the interleaved data were summed without additional phase correction. Approximately 10% of the spectra in the margin of VOI were discarded in subsequent analyses, which had the chemical-shift displacement effects arising from the use of PRESS 180 RF pulses with 1.4-kHz bandwidth. Spectral fitting was performed between 1.0 and 3.85 ppm with LCModel software, using in-house calculated basis spectra of 14 metabolites, which included 2HG, glutamate (Glu), glutamine (Gln), N-acetylaspartate (NAA), creatine þ phosphocreatine (tCr), glycine (Gly), myo-inositol (mI), glutathione (GSH), acetate (Ace), lactate (Lac), aspartate (Asp), scyllo-inositol (sI), N-acetylaspartylglutamate (NAAG), and glycerophosphorylcholine þ phosphorylcholine (tCho). The metabolite signal estimates from LCModel were normalized to the unsuppressed TE ¼ 13 ms stimulated echo acquisition mode water for individual voxels, which was to correct for potential B 1þ and B 1À variations; subsequently, the metabolite concentrations were calculated by scaling the normalized metabolite signal estimates with reference to tCr in normal-appearing gray-matter region at 8 mM. Metabolite estimates with Cramer-Rao lower bound (CRLB) greater than 20% were discarded, similarly as in previous EPSI studies (15, 17, 21) . Paired t-test was performed for comparison of metabolite estimates between tumor and contralateral regions with Bonferroni correction, using SAS software version 9.3 (SAS Institute, Cary, NC). Data are presented as mean 6 standard deviation.
RESULTS
The imaging performance of DRAG EPSI was compared with conventional phase-encoded MRSI and conventional EPSI in a GE Braino phantom (10 cm diameter). The VOI prescription was obtained with TE ¼ 78 ms PRESS for all imaging scans. The results are presented in Figure 2 , together with the spatial resolution (15 Â 15 mm 2 ), scan time (7 min), and spectral widths of the scans. The intensity and pattern of metabolite signals were in excellent agreement among the three methods, but the SNR was notably different among the methods, as shown in the NAA SNR maps. Compared with phase-encoded MRSI, the NAA SNR was 60 and 51% for DRAG EPSI and conventional EPSI, respectively, which is in good agreement with the theoretical values that were calculated from the plateau period and ramp time of the readout gradients (25) . In addition, we compared the DRAG-EPSI performance with conventional phase-encoded MRSI for a higher resolution (6 Â 6 mm 2 ), which was the same resolution as in our in vivo study. The readout gradients and consequently the spectral width of DRAG EPSI were also the same as in the in vivo study. The data are shown in Figure 3 . With the high-resolution imaging, both methods showed fairly uniform metabolite signals inside the phantom, without considerable signals from outside the phantom. Compared with the 15 Â 15 mm 2 resolution case, the NAA SNR in DRAG EPSI was increased to 81% with respect to the phase-encoded MRSI, which was caused by the longer plateau period of the readout gradients. The overall spectral pattern and signal strength were both essentially identical between the DRAG EPSI and phaseencoded MRSI.
We evaluated potential B 0 drifts induced by the readout gradients of DRAG EPSI and conventional EPSI in a phantom (6-cm diameter sphere). In each of the EPSI scans, 30 images were acquired, with a scan time of 1 min for each image. Figure 4 presents the results, together with the readout gradient parameters of the scans, which were set for equal resolution (6 Â 6 mm 2 ). The frequency drift was increased with time in each of the methods, but the drift was much smaller in DRAG EPSI than in conventional EPSI. The average drifts over the voxels within the phantom in DRAG EPSI and conventional EPSI were measured as 0.12 6 0.16 and 1.00 6 0.16 Hz at 16 min, and 0.38 6 0.17 and 1.64 6 0.21 Hz at 30 min, respectively.
The performance of DRAG-EPSI for 2HG detection was tested in a 6-cm-diameter spherical phantom with 2HG (10 mM) and Gly (20 mM negative polarity signal at 2.25 ppm, whereas the C3-proton signals between 1.8 and 2.0 ppm were diminished. When displayed for 1.8 to 2.4 ppm, the 2HG C4-proton signal was apparently uniform within the VOI. Spectral fitting by LCModel reproduced all spectra well. The 2HG-to-Gly ratio was estimated to be 0.49 6 0.02 within the phantom, reproducing the prepared concentration ratio of 1:2. The maps of 2HG and Gly estimates showed fairly uniform estimates within the phantom, giving a coefficient of variation (COV) of 2HG and Gly estimates at 3.7 and 4.2%, respectively.
The DRAG-EPSI method was used for imaging 2HG in five glioma patients (three IDH mutated, one unknown IDH mutational status, and one IDH wildtype). Figure 6 shows the data from a patient with IDH1 mutant oligodendroglioma (Patient 1). T 2 -weighted FLAIR identified a solid tumor mass in the left frontal region. The VOI was set at 60 Â 60 mm 2 , which included the tumor and contralateral volume. The RF field intensity was fairly homogeneous within the VOI (see B 1 map). The COV (standard deviation/mean) of B 1 within the VOI was 6.2%. The signals of NAA, tCr, and tCho were uniform outside the tumor region. The spectra from the tumor (upper-right region within VOI) were dominated by increased tCho signals. An inverted peak was clearly discernible at 2.25 ppm in spectra from the tumor (see the spectrum from location B), which should be attributed to 2HG given that the adjacent signals of Glu, Gln, and GABA are all positive at the PRESS echo-time condition (13). 2HG was estimated to be up to 5 mM in the tumor and was undetectable in the normal-appearing regions. The metabolite maps showed increase in tCho and decreases in NAA and tCr.
Data from another subject with IDH1 mutant oligodendroglioma are presented in Figure 7 . A tumor mass was identified in the right parietal region. The COV of B 1 within VOI was 6.6%. Many spectra within the tumor left-top to right-down exhibited relatively small metabolite signals, indicating that the region may be largely cystic. 2HG was clearly detectable with CRLB of less than 10% in most of the spectra from the tumor. The center of the tumor mass (location C) showed high 2HG (4.6 mM, CRLB 6%), and the right upper part of the tumor (location A) showed somewhat lower 2HG (3.1 mM, CRLB 6%). In contrast, the tCho level in this tumor was lower than normal (see tCho map). The tCho level was as low as 0.7 mM in the tumor (see spectrum from location C), which was quite lower than the levels in the normalappearing brain regions ($1.5 mM; see spectra from locations B and D). With the reduction of NAA in tumors, the tCho/NAA ratio was higher in the tumor than in contralateral (0.5-0.7 versus $0.1).
For the five patients in the present study, we calculated the mean value and standard deviation of B 1 within the VOI. The COV of B 1 was 3.8, 5.3, 6.2, 6.6, and 7.3%, giving a mean COV of 5.8 6 1.4%. The COV of B 0 was estimated to be 2.5, 3.6, 6.6, 13, and 16 Hz in the patients, with a mean COV at 8.3 6 5.9 Hz. For each of the five patients, the estimated concentrations of seven metabolites were averaged over the tumor volume and the normal-appearing contralateral volume. The result is shown in Figure 8 . 2HG was detectable in the three patients with biopsy-proven IDH mutant tumors (3.0 6 0.9, 3.3 6 0.4, and 2.3 6 0.6 mM in Patients 1, 2 and 3, respectively). 2HG was also clearly detected in a subject with radiographically suggested glioma (2.3 6 0.2 mM in Patient 4), indicating that this tumor may be an IDH mutant glioma. For these four tumors, the 2HG estimate difference between tumor and contralateral was significant (P < 0.001). In contrast, 2HG was undetectable in Patient 5, indicating that the lesion had wild-type IDH. After the MRS scan, the patient underwent a surgery and the lesion was found to be a primary glioblastoma, in which the incidence rate of IDH mutation is very low ( < 5%) (2, 3) . In four tumors other than Patient 2, the tCho level was estimated to be higher in tumors than in contralateral. The concentration of NAA was significantly lower in tumor than in contralateral brain in all cases. For Glx (Glu þ Gln), the concentration was significantly lower in tumor tissue than in contralateral brain in Patients 1, 2 and 3, but significantly elevated in the glioblastoma (Patient 5) (Gln $8 mM and Glu $3 mM).
DISCUSSION
We present high-resolution imaging of 2HG and other metabolites in brain tumor patients at 7 T, achieved using a newly designed EPSI scheme (DRAG EPSI). To our best knowledge, this is the first report of in vivo 7T imaging of 2HG in brain tumor patients, obtained with 6 Â 6 mm 2 in-plane resolution. A spectral width of 1638 Hz was achieved with relatively low gradient strengths. This spectral width with 6 Â 6 mm 2 in-plane resolution was not achievable using conventional EPSI, even when the slew rate was maximized to 200 mT/m/ FIG. 8. Comparison of the estimated concentrations of 2HG and four other metabolites in tumor versus normal-appearing contralateral brain in five glioma patients. Metabolite estimates, averaged over the volumes indicated by red and blue rectangles (tumor and contralateral respectively), are bar-graphed with standard deviation (error bars). Asterisks (*) indicate Bonferroni-corrected significant difference (P < 0.05/7), calculated with paired t-test. Glx denotes Glu þ Gln. ms in our 7T MR scanner, which may cause coil overheating and high acoustic noise, and consequently can aggravate data quality and patient compliance (31) . However, DRAG EPSI allowed us to use a readout gradient strength of 9.5 mT/m and a slew rate of 90 mT/m/ms, enjoying a decrease of acoustic noise level from 120 dB (conventional EPSI) to 80 dB (DRAG EPSI), as measured with a microphone placed inside the magnet. In addition, the data processing in DRAG EPSI is relatively straightforward. Because the data acquisition time points are identical between the positive and negative gradient data, these interleaved data can be directly summed following the eddy-current compensation using the DRAG-EPSI water data, without need of first-order phase correction, which may be required in time-shift EPSI (26, 27) .
When EPSI data are recorded only during the plateau period of readout gradients, the SNR penalty may occur relative to the usual continuous sampling, and the SNR efficiency, E SNR , can be calculated from the gradient plateau and ramp periods, as described in a previous study (25) . For the readout gradient strength and slew rate used in the present study and for in-plane resolution of 6 Â 6 mm 2 , E SNR of DRAG EPSI may be identical to that of conventional EPSI (81%) and is expected to be higher by approximately 33% compared with the dual-readout flyback EPSI, whose spectral width can be as high as 1865 Hz with a very large peak flyback gradient strength (220 mT/m). E SNR can be increased using a high slew rate. When the slew rate is increased to 150 mT/m/ms, which was used in the Cunningham et al study (25) , the E SNR of DRAG EPSI will be increased to 92% with readout gradient strength of 7.4 mT/m and spectral width of 1638 Hz. This spectral width may be easily achievable by dual-readout flyback EPSI using readout gradient strength of 4.6 mT/m and peak flyback gradient strength of 225 mT/m, and E SNR will be 83%, which is lower compared with DRAG EPSI. For conventional EPSI, the maximum achievable spectral width will be 1110 Hz using readout gradient strength of 16 mT/m, and E SNR will be 73%. Taken together, DRAG EPSI has advantages over conventional EPSI and dual-readout flyback EPSI in terms of E SNR and gradient stress.
In the present study, field inhomogeneities were minimized by performing B 0 shimming and B 1 calibration on the VOI. For the five subjects, the B 0 variation within VOI was 3 to 16 Hz, and the B 1 variations within VOI was 4 to 7% with respect to the mean B 1 . The average coefficient of variation of B 1 over five patients was 5.8%. For PRESS, the spectral pattern and strength of J-coupled resonances are sensitive to the flip angle of the refocusing RF pulses, whereas the flip-angle variation of the excitation RF pulse may have equal effects on the coupled and uncoupled spin signal strengths without altering the coupled-spin signal pattern. The effect of the refocusing pulse flip angle is more pronounced in strongly coupled resonances than in weakly coupled resonances. A refocusing pulse flip-angle range of 160 to 200 may correspond to a 95% confidence interval of the B 1 variation in this study (i.e., 1.96 Â 5.8% ¼ 11.4%). A simulation indicated that, when normalized to a singlet, the 2HG C2-proton signal at 4.02 ppm remains about the same for the flip-angle range, but the 2HG C4-proton signal is reduced as the flip angle deviates from 180 (see Fig. 9 ). The 2HG 2.25-ppm signal to singlet ratios at flip angles of 160 and 200 were 70 and 78%, respectively, with respect to that at the 180 flip angle. The average singlet linewidth over five subjects was 9 Hz. With 3-Hz apodization, the SNR was improved and the resulting linewidth was 12 Hz. Our previous study using the 2HG-optimized PRESS (13) showed that the 2HG 2.25-ppm signal can be reliably separated from adjacent signals up to a singlet linewidth of 12 Hz. Achievement of high B 1 homogeneity is challenging at 7 T. Uniform RF excitation may be achievable with adiabatic RF pulses for VOI prescription, similarly as in a previous single-voxel 2HG MRS study at 7 T (12), in which 5-to 6-s TR was used. Use of long TR, which is needed to meet the specific absorption rate requirement, hampers fast imaging of 2HG, whose signal is relatively small. In our study, without use of adiabatic RF pulse, the B 1 issue was alleviated with VOI-specific B 1 optimization.
The benefit of EPSI may be fully realized when metabolites are imaged with a much shorter scan time for a much higher matrix size imaging, compared with conventional phase-encoded MRSI. In our study, the data matrix size was 33 Â 30 with a scan time of 16 min. We chose to use a 2-s TR for metabolite quantification with relatively small variations in T 1 saturation effects across the brain metabolites, as the metabolite T 1 s are fairly long at 7 T ($1.8 s) (32) . For 33 Â 30 matrix size and 2-s TR, elliptically phase-encoded MRSI with single average may require an approximate 26-min scan time ( ¼ p/ 4 Â 33 min), which is 1.6-fold longer than our DRAG-EPSI scan time. Scan-time reduction benefit of DRAG EPSI with respect to conventional phase-encoded MRSI can be further realized in higher matrix imaging of 2HG (e.g., 3D imaging).
Because DRAG-EPSI requires dual readouts, the method has a loss in acceleration by a factor of 2 in such cases that conventional EPSI with single signal averaging per k-space point is sufficient. However, when multiple signal averaging is required for increasing SNR (as in the present study for measuring 2HG whose signals are relatively small), the data acquisitions may be split into two readouts without losing the acceleration factor compared with conventional EPSI.
Given the high clinical significance of 2HG, establishing a 2HG detection threshold may be clinically useful. It may require a rigorous analysis of many patient data from IDH mutant or wild-type tumors. With the limited number of patient data in the present study, we did not attempt to define the lower limit of 2HG detection, focusing on demonstration of new EPSI readout. Because detection of a metabolite depends on several factors, which include SNR, linewidth, interfering signals, and overall spectral baseline, a 2HG concentration threshold may not be easily definable. A most reliable threshold may be whether a 2HG signal is visually discernible in the spectrum. In this regard, the opposite signal polarity of 2HG with respect to the neighboring resonances of GABA and Glu, accomplished using the TE 78-ms PRESS at 7 T, may help improve 2HG detection compared with short-TE MRS at 7 T, as shown in our previous study (13) . In this previous study, 2HG at 1 mM or higher was detectable with CRLBs smaller than 7%. In the present study, we discarded metabolite estimates with CRLB greater than 20%, which usually corresponded to 2HG estimates of less than 0.5 mM.
Finally, the 2HG concentration was similar in Patients  1 and 2 (i.e., 3.0 and 3.3 mM) , but tCho, which is considered to be a marker of membrane turnover (33) , was approximately 3-fold higher in Patient 1 than in Patient 2 (2.9 versus 1.0 mM). A previous 2HG MRS study showed correlation of 2HG level with tumor cellularity in gliomas (11) . Lack of correlation between 2HG and tCho was reported in a previous 2HG study of 14 patients with IDH mutant gliomas (14) . These lines of observation suggest that 2HG production may be related to tumor cellularity, but may also be attributed to the differential competency of IDH mutant gliomas to produce 2HG.
CONCLUSIONS
In vivo high-resolution imaging of 2HG in glioma patients was achieved using a new 1 H-EPSI approach at 7 T. DRAG EPSI, with dual bipolar readout alternated gradients and simple data processing, offered increased spectral window and SNR compared with published EPSI methods. As a well-established biomarker for IDH mutant gliomas, high-resolution imaging of the oncometabolite 2HG has high diagnostic and prognostic value. The proposed 2HG imaging technique has potential application to monitor the 2HG levels in therapeutic drug trials targeting IDH inhibition in gliomas (34) (35) (36) .
